UY34178A - Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos. - Google Patents

Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.

Info

Publication number
UY34178A
UY34178A UY0001034178A UY34178A UY34178A UY 34178 A UY34178 A UY 34178A UY 0001034178 A UY0001034178 A UY 0001034178A UY 34178 A UY34178 A UY 34178A UY 34178 A UY34178 A UY 34178A
Authority
UY
Uruguay
Prior art keywords
paclitaxel
dosage
administration
treatment
combination
Prior art date
Application number
UY0001034178A
Other languages
English (en)
Inventor
Kubasek William
Moyo Victor
Macbeath Gavin
Pearlberg Joseph
Tabah-Fisch Isabelle
Original Assignee
Merrimack Pharmaceuticals Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Sanofi Sa filed Critical Merrimack Pharmaceuticals Inc
Publication of UY34178A publication Critical patent/UY34178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos y composiciones para el tratamiento clínico de cánceres ginecológicos avanzados usando anticuerpos anti-ErbB3 combinados con paclitaxel
UY0001034178A 2011-06-30 2012-06-29 Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos. UY34178A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161503342P 2011-06-30 2011-06-30
US201161529630P 2011-08-31 2011-08-31
FR1250860 2012-01-30
US201261596102P 2012-02-07 2012-02-07

Publications (1)

Publication Number Publication Date
UY34178A true UY34178A (es) 2013-01-31

Family

ID=47424747

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034178A UY34178A (es) 2011-06-30 2012-06-29 Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.

Country Status (15)

Country Link
US (1) US20140248280A1 (es)
EP (1) EP2726100A4 (es)
JP (1) JP2014527035A (es)
KR (1) KR20140063578A (es)
CN (1) CN103945866A (es)
AU (1) AU2012275850A1 (es)
BR (1) BR112013033544A2 (es)
CA (1) CA2839869A1 (es)
CO (1) CO6862110A2 (es)
EA (1) EA201490180A1 (es)
MA (1) MA35281B1 (es)
MX (1) MX2013015333A (es)
TW (1) TW201317002A (es)
UY (1) UY34178A (es)
WO (1) WO2013003037A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
MA38164B1 (fr) 2012-11-08 2018-11-30 Hoffmann La Roche Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3169708B1 (en) * 2014-07-16 2019-03-20 Dana-Farber Cancer Institute Inc. et Al. Her3 inhibition in low-grade serous ovarian cancers
KR20170137886A (ko) * 2015-04-17 2017-12-13 메리맥 파마슈티컬즈, 인크. 세리반투맙에 의한 병용 치료
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073629A2 (en) * 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR101798679B1 (ko) * 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도

Also Published As

Publication number Publication date
CA2839869A1 (en) 2013-01-03
JP2014527035A (ja) 2014-10-09
EP2726100A4 (en) 2015-04-29
WO2013003037A3 (en) 2014-05-01
MA35281B1 (fr) 2014-07-03
BR112013033544A2 (pt) 2017-12-19
AU2012275850A1 (en) 2013-03-21
CN103945866A (zh) 2014-07-23
TW201317002A (zh) 2013-05-01
EA201490180A1 (ru) 2014-08-29
WO2013003037A2 (en) 2013-01-03
KR20140063578A (ko) 2014-05-27
CO6862110A2 (es) 2014-02-10
MX2013015333A (es) 2014-07-09
EP2726100A2 (en) 2014-05-07
US20140248280A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
CL2017000310A1 (es) Anticuerpos anti tigit
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
EA201500314A1 (ru) Лекарственные формы энзалутамида
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
EA201400178A1 (ru) Лечение рака молочной железы
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020